Ponatinib is an inhibitor of BCR-ABL tyrosine kinase and is approved for the treatment of resistant CML and Philadelphia chromosome-positive ALL [35]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.